Mimma I. Rizzo

Bari, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 140 publications

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Journal: Frontiers in immunology

Published: February 26, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

Discovering Predictive Biomarkers in Renal Cell Carcinoma.

Discovering Predictive Biomarkers in Renal Cell Carcinoma.

Journal: European urology oncology

Published: February 17, 2026

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.

Journal: The oncologist

Published: February 08, 2026

Identification of Predictive Genomic Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis of Real-World Clinicogenomic Data.

Identification of Predictive Genomic Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis of Real-World Clinicogenomic Data.

Journal: JCO precision oncology

Published: January 23, 2026

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Journal: Clinical genitourinary cancer

Published: January 14, 2026

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Journal: International journal of cancer

Published: December 24, 2025

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: December 15, 2025

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project.

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project.

Journal: Clinical and experimental medicine

Published: November 25, 2025

Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".

Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".

Journal: International journal of cancer

Published: November 15, 2025

The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

Journal: Oncology research

Published: October 15, 2025

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Journal: Cancer immunology, immunotherapy : CII

Published: October 14, 2025

Showing 1-12 of 140

Last Updated: 09/26/2026